Antimicrobials
Voriconazole

Voriconazole

Restricted

Low
Excellent
$$(PO)/$$$(IV)/day

Dosing

General Information

Candida infections both mucocutaneous and invasive - i.e. Candidemia.

Antifungal prophylaxis in immunocompromised patients.

Therapeutic drug monitoring may be helpful to ensure adequate concentrations and exclude toxicity.  Target therapeutic level 2 or greater, target level to minimize toxicity is < 5.5.  

QTc interval in patients at elevated risk.

Monitor hepatic profile.

  • Drug interactions

  • QTc prolongation

  • Hepatic enzyme abnormalities

  • Rash - up to 20%

  • Visual disturbance

  • Fluorosis

  • GI upset

CYP450 interactions ++.

Other QTc prolonging agents.

Recommend review of pt medications due to high frequency of significant interactions.

  • Dose based on total body weight, if > 120% IBW use adjusted body weight.
  • Medication cost calculated per day (24 hours) of therapy for the average adult dose (70kg) of 200mg PO/IV q12h.

Antimicrobial class: Triazole antifungal, Second generation

Pregnancy category: D

Urine penetration: Poor

Lung penetration: Therapeutic

CSF penetration: Therapeutic